Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1333MR)

This product GTTS-WQ1333MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1333MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10546MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ7803MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ8226MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ12863MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ4868MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ9313MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ7664MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ9607MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61610588
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW